Table 3. Epidemiological changes in characteristics of children aged ≥24 months.
| 2018–2020 (n = 85) | 2021 (n = 65) | P-value | |
|---|---|---|---|
| Sex: male, n (%) | 40 (47.1) | 39 (60.0) | 0.138 |
| Palivizumab indication, n (%) | 0 (0) | 0 (0) | 1 |
| not indicated | 85 (100.0) | 65 (100.0) | |
| Palivizumab prophylaxis, n (%) | 0 (0) | 0 (0) | 1 |
| not administered | 85 (100.0) | 65 (100.0) | |
| Presence of siblings, n (%) | 39 (45.9) | 29 (44.6) | 0.833 |
| no siblings | 18 (21.2) | 15 (23.1) | |
| unknown | 28 (32.9) | 21 (32.3) | |
| Hospitalization duration | |||
| mean days (SD) | 5.04 (1.71) | 4.80 (1.88) | 0.431 |
| Oxygen use rate, n (%) | 24 (28.2) | 25 (38.5) | 0.22 |
| HFNC use rate, n (%) | 3 (3.5) | 3 (4.6) | 1 |
| Ventilator use rate, n (%) | 0 (0) | 0 (0) | NA |
| Mortality rate, n (%) | 0 (0) | 0 (0) | NA |
HFNC, high-flow nasal cannula; SD, standard deviation